The DOI matches its Crossref record.
Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum
Abstract
BACKGROUND: Treatment of hidradenitis suppurativa (HS) is difficult and the search for effective therapies continues. OBJECTIVES: To evaluate the efficacy of ustekinumab and to discover a potential biomarker for HS. METHODS: Seventeen patients were included in this open-label study and treated with 45 or 90 mg ustekinumab at weeks 0, 4, 16 and 28. Proteomic technology and enzyme-linked assay analysis was applied to sera. RESULTS: Twelve patients completed the protocol. Moderate-to-marked improvement of the modified Sartorius score was achieved in 82% of patients at week 40 and the Hidradenitis Suppurativa Clinical Response 50 in 47%. With regard to the expression of 54 serum proteins, at baseline, a significant difference was observed between patients and healthy controls. Involved pathways were related to inflammation, immune cell signalling and tissue morphology/development. Good responders had milder disease and lower expression of leukotriene A4-hydrolase (LTA4H). Interleukin (IL)-2R, tumour necrosis factor-α, IL-17A and IL-17F were not elevated and did not change during treatment. CONCLUSIONS: The majority of patients improved with ustekinumab. Although no biomarker was discovered, low LTA4H concentrations with mild disease severity may be predictive of the effectiveness of ustekinumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hidradenitis Suppurativa: Advances in Diagnosis and Treatment
Saunte, D. M. L., & Jemec, G. B. E. (2017) · JAMA · doi:10.1001/jama.2017.16691 · Cited by 492
Alikhan, A., Sayed, C., Alavi, A., Alhusayen, R., Brassard, A., Burkhart, C., Crowell, K., Eisen, D. B., Gottlieb, A. B., Hamzavi, I., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.067 · Cited by 400
Alikhan, A., Sayed, C., Alavi, A., Alhusayen, R., Brassard, A., Burkhart, C., Crowell, K., Eisen, D. B., Gottlieb, A. B., Hamzavi, I., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.068 · Cited by 399
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., Qiao, J., & Fang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594735 · Cited by 386
Emerging Topical and Systemic JAK Inhibitors in Dermatology
Solimani, F., Meier, K., & Ghoreschi, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02847 · Cited by 308
Winthrop, K. L., Mariette, X., Silva, J. T., Benamu, E., Calabrese, L. H., Dumusc, A., Smolen, J. S., Aguado, J. M., & Fernández-Ruiz, M. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.02.002 · Cited by 259
Zouboulis, C. C., Bechara, F. G., Dickinson‐Blok, J. L., Gulliver, W., Horváth, B., Hughes, R., Kimball, A. B., Kirby, B., Martorell, A., Podda, M., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15233 · Cited by 259
Self-citationHidradenitis suppurativa: from pathogenesis to diagnosis and treatment
Napolitano, M., Megna, M., Timoshchuk, E., Patruno, C., Balato, N., Fabbrocini, G., & Monfrecola, G. (2017) · Clinical, Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s111019 · Cited by 253
Hidradenitis Suppurativa: Where We Are and Where We Are Going
Scala, E., Cacciapuoti, S., Garzorz-Stark, N., Megna, M., Marasca, C., Seiringer, P., Volz, T., Eyerich, K., & Fabbrocini, G. (2021) · Cells · doi:10.3390/cells10082094 · Cited by 135
New and Emerging Targeted Therapies for Hidradenitis Suppurativa
Markota Čagalj, A., Marinović, B., & Bukvić Mokos, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073753 · Cited by 74
New treatment of pyoderma gangrenosum and hidradenitis suppurativa: A review
Yamanaka, K. (2024) · The Journal of Dermatology · doi:10.1111/1346-8138.17031 · Cited by 19
Transcriptomic Signatures and Molecular Pathways in Hidradenitis Suppurativa—A Narrative Review
Spiteri, J., Mintoff, D., Grech, L., & Pace, N. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167704 · Cited by 10
Metadata
- Authors
- Blok, J. L., Li, K., Brodmerkel, C., Horvátovich, P., Jonkman, M. F., & Horváth, B.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-27
- Volume
- 174
- Issue
- 4
- Pages
- 839-846
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W2192166578
- Cited by
- 193
- References
- 0
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.